Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : The trend should continue

09/23/2021 | 05:48am EDT
long trade
Stop-loss triggered
Entry price : 607.1$ | Target : 683.57$ | Stop-loss : 568.58$ | Potential : 12.6%
The recent break-out to the upside has created potential for further gains for shares in Thermo Fisher Scientific.
Investors have an opportunity to buy the stock and target the $ 683.57.
Thermo Fisher Scientific : Thermo Fisher Scientific : The trend should continue
  • The company has a good ESG score relative to its sector, according to Refinitiv.

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The group usually releases upbeat results with huge surprise rates.

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • With an expected P/E ratio at 33.61 and 34.46 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.

ę MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2021 36 041 M - -
Net income 2021 7 156 M - -
Net Debt 2021 18 490 M - -
P/E ratio 2021 32,3x
Yield 2021 0,17%
Capitalization 229 B 229 B -
EV / Sales 2021 6,87x
EV / Sales 2022 6,20x
Nbr of Employees 80 000
Free-Float 89,6%
Income Statement Evolution
Mean consensus BUY
Number of Analysts 21
Last Close Price 582,39 $
Average target price 642,29 $
Spread / Average Target 10,3%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors